BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16148699)

  • 1. Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?
    Hey C; Rose MA; Kujumdshiev S; Gstoettner W; Schubert R; Zielen S
    Laryngoscope; 2005 Sep; 115(9):1586-90. PubMed ID: 16148699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of pneumococcal vaccination of patients with cochlear implants.
    Rose M; Hey C; Kujumdshiev S; Gall V; Schubert R; Zielen S
    J Infect Dis; 2004 Aug; 190(3):551-7. PubMed ID: 15243931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
    Balmer P; Borrow R; Arkwright PD
    Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media.
    Bogaert D; Veenhoven RH; Ramdin R; Luijendijk IH; Rijkers GT; Sanders EA; de Groot R; Hermans PW
    Vaccine; 2005 Apr; 23(20):2607-13. PubMed ID: 15780443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation.
    Patel SR; Ortín M; Cohen BJ; Borrow R; Irving D; Sheldon J; Heath PT
    Clin Infect Dis; 2007 Mar; 44(5):625-34. PubMed ID: 17278051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.